← All drugs
Drug · FAERS side-effect profile with label screen

Sertraline Hydrochloride side effects: what 117,789 FDA adverse event reports show

Sertraline Hydrochloride · 1,184 reaction terms · 486,096 drug–reaction co-reports · data 2026-09-14
Share: X Facebook Reddit Email

Drug class

Not stated in label

Who reports

117,789 reports · 64% serious · 8,815 with death outcome · 69% female

openFDA FAERS counts, all years, deduplication not applied

Used for

Sertraline hydrochloride tablets are indicated for the treatment of the following [ See Clinical Studies ( 14 ) ]: • Major depressive disorder (MDD) • Obsessive-compulsive disorder (OCD) • Panic disorder (PD) • Posttraumatic stress disorder (PTSD) • So.

FDA label, Indications and Usage

What it is

Sertraline hydrochloride tablets, USP contain sertraline hydrochloride, an SSRI. Sertraline hydrochloride, USP has a molecular weight of 342.7 and has the following chemical name: (1S-cis)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-N-methyl-1-naphthalenamine hydrochloride.

FDA label, Description section

Boxed warning

SUICIDAL THOUGHTS AND BEHAVIORS Antidepressants increased the risk of suicidal thoughts and behavior in pediatric and young adult patients in short-term studies. Closely monitor all antidepressant-treated patients for clinical worsening, and for emergence of suicidal thoughts and behaviors [ See Warnings and Precautions ( 5.1 ) ].

FDA label
How to read this page. FAERS is a spontaneous-reporting system: counts are not incidence rates and a signal is not proof of causation. Each reaction below is run through an automated screen — is the term in the FDA label (known), in the indications (the disease being treated), an administrative/coding term, or none of these (unlabeled)? That screen is mechanical text matching, not a causality assessment. The 30 hand-written Bradford Hill assessments are on the causality assessment page. Not medical advice.

Causality screen of the 40 strongest signals

Labeled — boxed warning 1Labeled adverse reaction 3Labeled (related wording) 4Likely indication confounding 3Reporting / coding artifact 1Lab value / disease marker 1Not in label — unassessed 27
What the badges mean

Strongest disproportionality signals

Flagged terms (PRR ≥ 2, χ² ≥ 4, n ≥ 10), ranked by PRR; infinite PRRs (no comparator reports) excluded. The EBGM column is a second, shrinkage-based estimate (MGPS) with its 5th percentile EB05 and the BCPNN IC025; a pair flagged by PRR alone is marked PRR-only and should be read as fragile. The strata column recomputes the PRR on serious reports only (and, for the 300 most-reported drugs, adjusted for age band), and flags pairs whose reports are unusually skewed by sex or come mostly from consumers. Each row also shows the PRR against the other drugs of the same FDA class, which removes most confounding by the condition being treated, and a calibrated p-value: on validation, known non-causes average an ROR of about 2, so significance is judged against that empirical null (✓ = p < 0.05 after calibration). 1,144 further terms are in the interactive explorer. Reaction links open the term's cross-drug page.

Show:
ReactionReportsPRR 95% CI · ROR · χ²/pEBGM EB05 · IC025Label screenSerious-only & strataTrial cross-check
Multiple acyl-coenzyme a dehydrogenase deficiency10663.4
50.8–79.2ROR 63.4 · calibrated p 4e-6 ✓
46.4 EB05 39.5 · IC025 +4.9
3/3 methods agree
Not in label — unassessedserious n=106 · ♀ 100% (drug 69%) · 100% cliniciannot reported in cached trials
Amaurosis fugax16331.9
27.0–37.7ROR 31.9 · calibrated p 2e-4 ✓
27.0 EB05 23.7 · IC025 +4.4
3/3 methods agree
Not in label — unassessedserious n=163 · 100% cliniciannot reported in cached trials
Feeling guilty20031.5
27.1–36.6ROR 31.5 · calibrated p 2e-4 ✓
26.8 EB05 23.8 · IC025 +4.4
3/3 methods agree
Not in label — unassessed100% consumernot reported in cached trials
Feelings of worthlessness19731.2
26.8–36.3ROR 31.2 · calibrated p 2e-4 ✓
26.6 EB05 23.6 · IC025 +4.4
3/3 methods agree
Not in label — unassessed100% consumernot reported in cached trials
Maternal exposure timing unspecified54730.6
27.9–33.5ROR 30.7 · calibrated p 2e-4 ✓
26.1 EB05 24.4 · IC025 +4.5
3/3 methods agree
Reporting / coding artifactserious n=542 · ♀ 46% (drug 69%)not reported in cached trials
Transposition of the great vessels8922.4
18.0–27.9ROR 22.4 · calibrated p 0.001 ✓
19.9 EB05 16.6 · IC025 +3.8
3/3 methods agree
Not in label — unassessedserious n=89 · ♀ 0% (drug 69%)not reported in cached trials
Phobia9315.5
12.6–19.2ROR 15.5 · calibrated p 0.007 ✓
14.3 EB05 12.0 · IC025 +3.4
3/3 methods agree
Not in label — unassessed100% consumernot reported in cached trials
Patent ductus arteriosus30914.9
13.2–16.7ROR 14.9 · calibrated p 0.007 ✓
13.8 EB05 12.5 · IC025 +3.6
3/3 methods agree
Not in label — unassessedserious n=309 · ♀ 49% (drug 69%)not reported in cached trials
Negative thoughts21714.1
12.3–16.2ROR 14.1 · calibrated p 0.009 ✓
13.1 EB05 11.7 · IC025 +3.5
3/3 methods agree
Not in label — unassessedserious n=69 · 100% consumernot reported in cached trials
Heart disease congenital25813.8
12.1–15.7ROR 13.8 · calibrated p 0.010 ✓
12.8 EB05 11.5 · IC025 +3.4
3/3 methods agree
Not in label — unassessedserious n=257not reported in cached trials
Ventricular septal defect36812.1
10.9–13.4ROR 12.1 · calibrated p 0.016 ✓
11.3 EB05 10.4 · IC025 +3.3
3/3 methods agree
Not in label — unassessedserious n=368 · 100% cliniciannot reported in cached trials
Atrial septal defect52611.8
10.8–12.9ROR 11.9 · calibrated p 0.018 ✓
11.1 EB05 10.3 · IC025 +3.3
3/3 methods agree
Not in label — unassessedserious PRR 10.1not reported in cached trials
Cleft palate12111.8
9.8–14.2ROR 11.8 · calibrated p 0.019 ✓
11.0 EB05 9.4 · IC025 +3.1
3/3 methods agree
Not in label — unassessedserious n=120 · ♀ 0% (drug 69%)not reported in cached trials
Talipes19411.8
10.2–13.6ROR 11.8 · calibrated p 0.018 ✓
11.0 EB05 9.8 · IC025 +3.2
3/3 methods agree
Not in label — unassessedserious n=193 · ♀ 42% (drug 69%)not reported in cached trials
Neuritis9411.5
9.3–14.2ROR 11.5 · calibrated p 0.021 ✓
10.7 EB05 8.9 · IC025 +3.0
3/3 methods agree
Labeled adverse reaction
exact term
serious n=93 · ♀ 0% (drug 69%) · 100% cliniciannot reported in cached trials
Congenital anomaly47011.4
10.3–12.5ROR 11.4 · calibrated p 0.020 ✓
10.7 EB05 9.9 · IC025 +3.3
3/3 methods agree
Not in label — unassessedserious PRR 9.7 · ♀ 44% (drug 69%)not reported in cached trials
Decreased interest35511.3
10.2–12.6ROR 11.4 · calibrated p 0.021 ✓
10.7 EB05 9.7 · IC025 +3.2
3/3 methods agree
Not in label — unassessedserious n=120 · 85% consumernot reported in cached trials
Homicidal ideation22610.4
9.1–11.9ROR 10.4 · calibrated p 0.029 ✓
9.8 EB05 8.8 · IC025 +3.1
3/3 methods agree
Not in label — unassessedserious n=217not reported in cached trials
Drug screen false positive1409.3
7.9–11.1ROR 9.3 · calibrated p 0.042 ✓
8.8 EB05 7.6 · IC025 +2.8
3/3 methods agree
Lab value / disease marker–not reported in cached trials
Psychomotor skills impaired1319.3
7.8–11.1ROR 9.3 · calibrated p 0.043 ✓
8.7 EB05 7.5 · IC025 +2.8
3/3 methods agree
Not in label — unassessedserious n=129 · ♀ 0% (drug 69%) · 100% cliniciannot reported in cached trials
Serotonin syndrome9419.2
8.6–9.8ROR 9.2 · calibrated p 0.042 ✓
8.7 EB05 8.3 · IC025 +3.0
3/3 methods agree
Labeled — boxed warning
exact term
age-adj. PRR 7.6 · serious PRR 7.9NCT00605865: 1/2,157 (0.0%) on Sertraline (serious AE)
Biliary dyskinesia839.0
7.2–11.2ROR 9.0 · calibrated p 0.048 ✓
8.4 EB05 6.9 · IC025 +2.7
3/3 methods agree
Not in label — unassessedserious n=83 · ♀ 100% (drug 69%) · 100% consumernot reported in cached trials
Tension2918.9
7.9–10.0ROR 8.9 · calibrated p 0.048 ✓
8.4 EB05 7.6 · IC025 +2.9
3/3 methods agree
Labeled adverse reaction
exact term
serious n=70 · 86% consumerNCT00605865: 2/2,157 (0.1%) on Sertraline
Obsessive thoughts868.8
7.1–11.0ROR 8.8 · calibrated p 0.051
8.2 EB05 6.8 · IC025 +2.7
3/3 methods agree
Likely indication confounding
shares a disease stem with the indications wording
serious n=73 · ♀ 0% (drug 69%) · 100% consumernot reported in cached trials
Flat affect1088.8
7.3–10.7ROR 8.8 · calibrated p 0.051
8.2 EB05 7.0 · IC025 +2.7
3/3 methods agree
Not in label — unassessedserious n=76 · 100% consumernot reported in cached trials
Neonatal respiratory distress syndrome1688.8
7.5–10.3ROR 8.8 · calibrated p 0.051
8.3 EB05 7.3 · IC025 +2.8
3/3 methods agree
Not in label — unassessedserious n=168 · ♀ 41% (drug 69%) · 100% cliniciannot reported in cached trials
Psychiatric decompensation928.8
7.1–10.8ROR 8.8 · calibrated p 0.052
8.2 EB05 6.8 · IC025 +2.7
3/3 methods agree
Not in label — unassessedserious n=91 · ♀ 0% (drug 69%) · 100% cliniciannot reported in cached trials
Anorgasmia1258.5
7.1–10.2ROR 8.5 · calibrated p 0.056
8.0 EB05 6.9 · IC025 +2.7
3/3 methods agree
Not in label — unassessedserious n=87 · 100% consumernot reported in cached trials
Bruxism2468.5
7.4–9.6ROR 8.5 · calibrated p 0.057
8.0 EB05 7.2 · IC025 +2.8
3/3 methods agree
Labeled adverse reaction
exact term
serious n=179not reported in cached trials
Obsessive-compulsive disorder3548.1
7.3–9.0ROR 8.1 · calibrated p 0.064
7.7 EB05 7.1 · IC025 +2.8
3/3 methods agree
Likely indication confounding
term in indications
serious n=292 · ♀ 49% (drug 69%)not reported in cached trials
Major depression3067.7
6.9–8.7ROR 7.7 · calibrated p 0.075
7.4 EB05 6.7 · IC025 +2.7
3/3 methods agree
Likely indication confounding
shares a disease stem with the indications wording
serious PRR 6.7not reported in cached trials
Attention deficit/hyperactivity disorder1367.7
6.5–9.1ROR 7.7 · calibrated p 0.077
7.2 EB05 6.3 · IC025 +2.6
3/3 methods agree
Not in label — unassessedserious n=115 · ♀ 43% (drug 69%)not reported in cached trials
Diabetic neuropathy2067.6
6.6–8.8ROR 7.7 · calibrated p 0.077
7.3 EB05 6.5 · IC025 +2.6
3/3 methods agree
Not in label — unassessedserious n=202not reported in cached trials
Cholecystitis chronic2757.5
6.6–8.4ROR 7.5 · calibrated p 0.082
7.1 EB05 6.5 · IC025 +2.6
3/3 methods agree
Not in label — unassessedserious PRR 6.5 · ♀ 100% (drug 69%)not reported in cached trials
Urinary tract disorder1827.5
6.4–8.7ROR 7.5 · calibrated p 0.083
7.1 EB05 6.3 · IC025 +2.6
3/3 methods agree
Not in label — unassessedserious n=168 · 100% cliniciannot reported in cached trials
Apathy5797.3
6.8–8.0ROR 7.4 · calibrated p 0.085
7.1 EB05 6.6 · IC025 +2.7
3/3 methods agree
Not in label — unassessedage-adj. PRR 4.5 · serious PRR 3.8 · 77% consumernot reported in cached trials

Clinical concept groups

MedDRA splits one clinical problem across several terms (e.g. "neutropenia", "neutrophil count decreased", "agranulocytosis"), which dilutes term-level signals. These rows count reports with any term in a concept group (an exact union, not a sum), compared with all other drugs. Groups are hand-built and listed in the methods.

ConceptReportsPRR 95% CIReading
Depression7,4684.84.7–4.9signal
Suicidality5,8734.34.2–4.4signal
Extrapyramidal1,7373.02.8–3.1signal
Hyponatraemia1,1662.62.5–2.8signal
Fall / fracture4,5152.12.1–2.2signal
Seizure2,0901.91.8–2.0raised
Pancreatitis8561.91.8–2.0raised
Venous thromboembolism2,0911.71.7–1.8raised
Hyperglycaemia / diabetes3,2561.71.6–1.7raised
Rhabdomyolysis / myopathy7141.61.5–1.7raised
Gi bleeding1,5541.51.4–1.6raised
Arrhythmia / qt1,6261.51.4–1.6raised
Serious infection6,0761.41.4–1.4raised
Dependence / withdrawal2,2581.41.3–1.4raised
Anaemia2,2651.31.3–1.4raised
Heart failure1,3121.31.2–1.4raised

Trial evidence (ClinicalTrials.gov)

✓ Trial adverse-event data found on ClinicalTrials.gov

Largest completed trials with posted results that list Sertraline as a study intervention. The right-hand column of the signal table shows whether each FAERS term was also recorded in these trials, with a real denominator (2 of 40 signal terms matched).

Caveats: trial populations, doses and follow-up differ from the reporting population; AE terms are sponsor-coded and matched here by wording; absence from a trial list means the term was not reported above the sponsor's frequency threshold, not that it cannot occur.

Most frequently reported reactions

By raw co-report count, regardless of disproportionality. Common terms here are often the illness itself or generic outcomes.

ReactionReportsPRR 95% CI · ROR · χ²/pEBGM EB05 · IC025Label screenSerious-only & strataTrial cross-check
Drug ineffective (drug did not work)8,1901.1
1.1–1.1ROR 1.1 · calibrated p 0.383
1.1 EB05 1.1 · IC025 +0.1Reporting / coding artifactage-adj. PRR 1.2 · serious PRR 1.2not reported in cached trials
Nausea8,1591.8
1.8–1.9ROR 1.9 · calibrated p 0.895
1.8 EB05 1.8 · IC025 +0.8Labeled adverse reaction
exact term
age-adj. PRR 1.6 · serious PRR 2.0NCT00605865: 87/2,157 (4.0%) on Sertraline
Fatigue (tiredness)7,6601.8
1.7–1.8ROR 1.8 · calibrated p 0.839
1.8 EB05 1.7 · IC025 +0.8Labeled adverse reaction
exact term
age-adj. PRR 1.5 · serious PRR 1.8not reported in cached trials
Headache6,7871.9
1.9–2.0ROR 2.0 · calibrated p 0.942
1.9 EB05 1.9 · IC025 +0.9Labeled adverse reaction
exact term
age-adj. PRR 1.7 · serious PRR 2.2NCT00605865: 8/2,157 (0.4%) on Sertraline
Anxiety6,4274.1
4.0–4.2ROR 4.3 · calibrated p 0.333
4.0 EB05 3.9 · IC025 +2.0
3/3 methods agree
Likely indication confounding
term in indications; also in warnings
age-adj. PRR 3.7 · serious PRR 3.9NCT00605865: 4/2,157 (0.2%) on Sertraline
Depression6,3295.0
4.9–5.2ROR 5.3 · calibrated p 0.207
4.9 EB05 4.8 · IC025 +2.3
3/3 methods agree
Labeled — boxed warning
synonym match
age-adj. PRR 4.4 · serious PRR 5.0not reported in cached trials
Diarrhoea (diarrhea)5,6881.6
1.5–1.6ROR 1.6 · calibrated p 0.712
1.6 EB05 1.5 · IC025 +0.6Labeled adverse reaction
exact term
age-adj. PRR 1.5 · serious PRR 1.6NCT00605865: 27/2,157 (1.3%) on Sertraline
Dizziness5,5122.0
1.9–2.0ROR 2.0 · calibrated p 0.960
2.0 EB05 1.9 · IC025 +0.9Labeled adverse reaction
exact term
age-adj. PRR 1.8 · serious PRR 2.2NCT00605865: 8/2,157 (0.4%) on Sertraline
Pain5,4511.6
1.5–1.6ROR 1.6 · calibrated p 0.713
1.6 EB05 1.5 · IC025 +0.6Labeled adverse reaction
exact term
age-adj. PRR 1.7 · serious PRR 1.6NCT00605865: 2/2,157 (0.1%) on Sertraline
Dyspnoea (shortness of breath)4,8771.5
1.5–1.6ROR 1.6 · calibrated p 0.682
1.5 EB05 1.5 · IC025 +0.6Not in label — unassessedage-adj. PRR 1.4 · serious PRR 1.5NCT00605865: 3/2,157 (0.1%) on Sertraline
Insomnia (trouble sleeping)4,4643.0
2.9–3.1ROR 3.1 · calibrated p 0.597
3.0 EB05 2.9 · IC025 +1.5
3/3 methods agree
Labeled adverse reaction
exact term
age-adj. PRR 2.6 · serious PRR 3.2NCT00605865: 2/2,157 (0.1%) on Sertraline
Vomiting4,4511.7
1.6–1.7ROR 1.7 · calibrated p 0.784
1.7 EB05 1.6 · IC025 +0.7Labeled adverse reaction
exact term
age-adj. PRR 1.5 · serious PRR 1.7NCT00605865: 2/2,157 (0.1%) on Sertraline
Fall4,2502.3
2.2–2.4ROR 2.3 · calibrated p 0.884
2.3 EB05 2.2 · IC025 +1.1
3/3 methods agree
Labeled adverse reaction
exact term
age-adj. PRR 2.2 · serious PRR 2.1NCT00605865: 1/2,157 (0.0%) on Sertraline (serious AE)
Asthenia (weakness)4,1862.0
1.9–2.1ROR 2.0 · calibrated p 0.960
2.0 EB05 1.9 · IC025 +0.9Not in label — unassessedage-adj. PRR 1.8 · serious PRR 1.9not reported in cached trials
Off label use (used outside approved label)4,0610.8
0.8–0.9ROR 0.8 · calibrated p 0.199
0.8 EB05 0.8 · IC025 -0.3
PRR-only: not supported by EBGM or IC
Reporting / coding artifactage-adj. PRR 0.8 · serious PRR 0.9not reported in cached trials

Unlabeled candidate signals

These flagged terms were not found in the FDA label text and do not match an artifact pattern. They are the pairs that would merit a structured assessment (temporality, dose-response, biological plausibility, consistency across databases, trial or cohort evidence). The screen has not done that; string-matching misses label wording, and a strong PRR can still be stimulated reporting, co-medication, or the disease itself.

✓ A hand-written Bradford Hill causality assessment exists for this drug: Sertraline (SSRIs) ↔ Upper gastrointestinal bleeding.

Want to assess one of these properly? The runbook describes the Bradford Hill / trial-evidence workflow used on the assessment page, and handoff_top1000_signals.csv lists the strongest unassessed pairs across all drugs.

Common questions

What are the most reported side effects of Sertraline?

In FDA FAERS, the most frequently co-reported reaction terms for Sertraline are nausea, fatigue, headache, anxiety, depression, diarrhoea. These are report counts, not rates: FAERS has no denominator, reporting is voluntary and uneven, and a term can be reported because of the illness being treated rather than the drug.

Does Sertraline have an FDA boxed warning?

Yes. The current FDA label carries a boxed warning: SUICIDAL THOUGHTS AND BEHAVIORS Antidepressants increased the risk of suicidal thoughts and behavior in pediatric and young adult patients in short-term studies. Closely monitor all antidepressant-treated patients for clinical worsening, and for emergence of suicidal thoughts and behaviors [ See Warnings and Precautions ( 5.1 ) ].

Do FAERS signals prove that Sertraline causes these side effects?

No. A disproportionality signal (PRR, ROR) means a reaction is reported more often with this drug than with others in the database. That can reflect a real effect, but also the disease being treated, stimulated reporting after news or litigation, co-medications, or how reports are coded. Causality needs temporality, dose-response, biological plausibility, consistency across data sources and, ideally, trial or cohort evidence. This page screens each term against the FDA label and ClinicalTrials.gov results; it does not establish causation.

Sources & methods

Page generated 2026-10-14. Label and PubChem text are retrieved automatically and may lag the current label; always check the current prescribing information. OpenPV is a beta research tool of the Open Source Medicine Foundation.